Research
Name | Type | Target | Compound Name | Phase |
---|---|---|---|---|
Michigan State University
High Accuracy Modeling of SARS-CoV-2 Membrane Proteins via Machine Learning and Physics-Based Refinement |
Research (Modeling) | N/A | N/A | Research |
University of California, Riverside
Harnessing Large-Scale Quantum-Based DFTB Calculations for a More Accurate Assessment of COVID-19 Inhibitors and Their Binding Dynamics |
Research (Modeling) | N/A | N/A | Research |
University of California, Riverside
Computer-aided drug discovery for SARS-CoV-2 |
Research (AI) | N/A | N/A | Pre-Clinical |
Emory University
Characterization and structures of the SARS-CoV-2 polymerase and its complex with RNA or potential inhibitors |
Research (Modeling) | N/A | N/A | Research |
Kaiser Family Foundation (KFF)
Communities of Color at Higher Risk for Health and Economic Challenges due to COVID-19 |
Research (Epidemiology) | N/A | N/A | Pre-Clinical |
Imperial College COVID-19 Response Team
Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand |
Research (Epidemiology) | N/A | N/A | Research |
Collaboration: The University of Hong Kong; Harvard T.H. Chan School of Public Health
Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China |
Research (Epidemiology) | N/A | N/A | Pre-Clinical |
Collaboration: Michigan State University; University of Illinois at Chicago;
Decoding SARS-CoV-2 transmission, evolution and ramification on COVID-19 diagnosis, vaccine, and medicine |
Research (Modeling) | N/A | N/A | Pre-Clinical |
IQVIA
This COVID-19 Active Cases Curve Simulator has been developed by the IQVIA Data Science and Advanced Analytics team as a tool to help stakeholders make decisions based on the level and trajectory of active cases in their country, region or state. |
Research (Modeling) | N/A | N/A | Research |
Collaboration: Women’s Hospital Heart and Vascular Center; Harvard Medical School; Baylor College of Medicine; Christ Hospital; University of Utah; HCA Research Institute
Using an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug therapy with in-hospital death among hospitalized patients with COVID-19 |
New Therapies (Antibody-based) | N/A | N/A | Pre-Clinical |
Grifols
Grifols collecting plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat COVID-19 disease. |
New Therapies (Small Molecule) | N/A | Alpha-1 antitrypsin | Pre-Clinical |
Kerecis
Kerecis Begins Omega3 Viruxide COVID-19 Trial at the National Hospital of Iceland |
New Therapies (Lipid) | N/A | Omega3 Viruxide | In Clinic |
Revive
The FDA recommended that Revive Therapeutics proceed directly into a Phase 3 confirmatory clinical trial (“Phase 3 study”) to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection in order to ensure expeditious evaluation of the safety and efficacy of Bucillamine. |
N/A | Bucillamine | Phase III | |
Shenyang Tonglian
The Clinical Study of Carrimycin on Treatment Patients With COVID-19 |
New Therapies (Small Molecule) | N/A | Carrimycin | Phase IV |
CUNY Institute for Implementation Science in Population Health
The study team moved quickly to enroll a prospective cohort of >7,000 individuals using internet-based strategies. The cohort represents a geographically and socio-demographically diverse sample of the adult U.S. population: 23 percent of participants were 60+ years at enrollment, 24 percent are Black or Hispanic, and 52 percent are men. At least 24 percent of participants are frontline workers, either in healthcare or other essential employees such as police, first responders, people in food services or transportation. All fifty U.S. states are represented, as well as the District of Columbia, Puerto Rico, and Guam. |
Research (Epidemiology) | N/A | N/A | Research |
Collaboration: Cytovia; Macromoltek
Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19) |
New Therapies (Antibody-based) | NCR1, NKP46, CD335 | NK activating Abs + neutralizing antibodies | Pre-Clinical |
Vanda Pharmaceuticals
Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia |
New Therapies (Protein-based) | NK1R; TACR1 | Tradipitant | Phase III |
Algernon Pharmaceuticals
Toxicology studies initiated for anti-inflammatory drug ifenprodil |
Research (Drug Repurposing) | NMDA receptor NR2B (GRIN2B; NR2B; GluN2B) | Ifenprodil (NP-120) | IND |
Fasa University of Medical Sciences
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 |
New Therapies (Small Molecule) | Nicotinic acetylcholine receptor (nAchR) | Levamisole | Phase II / III |
Vanda Pharmaceuticals
Amantadine disrupts lysosomal gene expression; potential therapy for COVID19 |
New Therapies (Small Molecule) | Not determined | Amantadine | Pre-Clinical |
Cleveland Clinic
Network-based drug re-purposing for novel coronavirus 2019-nCoV/SARS-CoV-2 |
New Therapies (Small Molecule) | Not determined | Dactinomycin | Pre-Clinical |
Cleveland Clinic
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 |
New Therapies (Small Molecule) | Not determined | Mercaptopurine | Pre-Clinical |
Starpharma
Starpharma’s antiviral dendrimer, SPL7013, has been shown to have significant activity against SARS-CoV-21 (coronavirus), which causes COVID-19 |
New Therapies (Small Molecule) | Not determined | VivaGel | Pre-Clinical |
WanBangDe Pharmaceutical
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) |
New Therapies (Small Molecule) | Not determined | Bromhexine hydrochloride | In Clinic |
FirstWave
FirstWave Bio to Initiate Phase 2a/2b Study of FW-1022, a Proprietary Form of Niclosamide, to Treat COVID-19 |
New Therapies (Small Molecule) | Not determined | FW-1022 (oral niclosamide) | Phase II |